In Re Maxim Integrated Products, Inc., Deriv. Lit.

574 F. Supp. 2d 1046, 2008 U.S. Dist. LEXIS 69527, 2008 WL 4061075
CourtDistrict Court, N.D. California
DecidedAugust 27, 2008
DocketC 06-03344 JW
StatusPublished
Cited by12 cases

This text of 574 F. Supp. 2d 1046 (In Re Maxim Integrated Products, Inc., Deriv. Lit.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Maxim Integrated Products, Inc., Deriv. Lit., 574 F. Supp. 2d 1046, 2008 U.S. Dist. LEXIS 69527, 2008 WL 4061075 (N.D. Cal. 2008).

Opinion

ORDER GRANTING IN PART AND DENYING IN PART DEFENDANTS’ MOTIONS TO DISMISS; DENYING PLAINTIFF’S MOTION TO STAY DISCOVERY

JAMES WARE, District Judge.

I. INTRODUCTION

This is a shareholders’ derivative action brought on behalf of Nominal Defendant Maxim Integrated Products, Inc. (“Maxim” or the “Company”) against current and former officers and directors of the Company (collectively, “Individual Defendants”) 1 for, inter alia, alleged violations *1055 of §§ 10(b), 14(a), and 20(a) of the Securities Exchange Act. Plaintiffs 2 allege that the Individual Defendants engaged in a scheme to manipulate stock option grant dates so as to maximize profits to themselves at the expense of the Company.

Presently before the Court are Motions to Dismiss by various Defendants and a Motion to Stay Discovery in related state court actions by Plaintiffs. The Court conducted a hearing on February 1, 2008. Based on the papers submitted to date and oral argument, the Court GRANTS in part and DENIES in part Defendants’ Motions to Dismiss and DENIES Plaintiffs’ Motion to Stay Discovery.

II. BACKGROUND

A. Factual Allegations

In a Second Amended Complaint filed on August 31, 2007, Plaintiffs allege as follows:

From 1994 through 2006, Defendants backdated stock option grants to coincide with historically and relatively low closing prices of Maxim’s common stock. (Corrected Second Amended Verified Consolidated Shareholder Derivative Complaint ¶ 12, hereafter, “SAC,” Docket Item No. 132.) Defendants did not properly account for the compensation expenses associated with these options grants. (Id. ¶ 4.) Defendants issued false and misleading financial statements which misrepresented the true state of Maxim’s financial performance. (Id. ¶ 6.)
Defendants’ illegal and fraudulent options backdating practices were revealed on May 22, 2006, when Merrill Lynch published a report concerning the option grants at several semi-conductor companies, including Maxim. (Id. ¶ 171.) The Merrill Lynch report showed that the option grants suspiciously coincided with historical or relative lows in the Company’s stock, a result that would not be expected if options grants were not backdated. (SAC, Ex. B, Docket Item No. 137.)
After the report was released, the SEC and the United States Attorney for the Northern District of California launched investigations into Maxim’s stock option granting practices. (SAC ¶¶ 172-173.) Additionally, Maxim appointed a special committee to conduct an internal investigation into the Company’s stock option granting practices. (Id. ¶ 174.) As a result of the investigation, Maxim did not file its annual or quarterly reports in 2006. (Id. ¶¶ 174-175.) In January 2007, Maxim announced the results of its investigation. (Id. ¶ 180.) The Special Committee found that grants to officers were properly granted, but that grants to directors and other employees were not properly accounted for. (Id.) Maxim announced that it would restate its results for 2000 through 2006, but that it had not determined by how much. (Id.) On August 30, 2007, Maxim announced that it had not yet determined the amount of its restatement and that it would not file its annual report for 2007.(Id.)

On the basis of the allegations outlined above, Plaintiffs allege ten causes of action:

Cause of Action Defendants
(1) Fraud in violation of Bergman, Byrd, Gifford, § 10(b) and Rule 10b-5 of Hagopian, Karros, Sampels, the Securities Exchange and Wazzan Act
(2) Issuance of false Bergman, Byrd, Gifford, proxy statements in viola- Hagopian, Karros, Sampels, *1056 tion of § 14(a) of the and Wazzan Securities Exchange Act_
(3) Control person liabili- Bergman, Byrd, Gifford, ty under § 20(a) of the Hagopian, Jasper, Karros, Securities Exchange Act Sampels, and Wazzan_
(4) Accounting_All Defendants_
(5) Breach of Fiduciary All Defendants Duty and/or Aiding and Abetting
(6) Unjust Enrichment All Defendants
(7) Rescission All Defendants
(8) Insider Selling and Beck, Bergman, Boyaeigiller, Misappropriation Byrd, Doluca, Georges, Ghaffaripour, Gifford, Gilbert, Hagopian, Hale, Hood, Huening, Jasper, Levin, Neil, Parvarandeh, Rigg, Sampels, Scheer, Ullal, Wazzan, and Zekeriya
(9) Insider trading in vio- Beck, Bergman, Boyaeigiller, lation of California Cor- Byrd, Doluca, Georges, porations Code §§ 25402 Ghaffaripour, Gifford, and 25502.5 Gilbei-t, Hagopian, Hale, Hood, Huening, Jasper, Levin, Neil, Parvarandeh, Rigg, Sampels, Scheer, Ullal, Wazzan, and Zekeriya
(10) Breach of Fiduciary Beck, Bergman, Boyaeigiller, Duty in connection with Byrd, Doluca, Georges, insider trading Ghaffaripour, Gifford, Gilbert, Hagopian, Hale, Hood, Huening, Jasper, Levin, Neil, Parvarandeh, Rigg, Sampels, Scheer, Ullal, Wazzan, and Zekeriya

B.Stock Option Granting, Dating and Pricing

A stock option granted to an employee of a corporation allows the employee to purchase at some future date a specified number of shares of corporate stock at a specified price, called the “exercise price.” If the exercise price is the same as the market price of the stock on the date the option is granted, the option is said to be “at-the-money.” Under Generally Accepted Accounting Principles (“GAAP”), a company that grants an option “at-the-money” is not required to record the grants as compensation expenses. On the other hand, if the exercise price of the option is less than the market price of the stock on the date the option is granted, the options is said to be “in-the-money.” Under GAAP, the company must record a compensation expense for the “in-the-money” option grant, equal to the difference between the exercise price and the market price of the stock on the date the option is granted. Walter L. Lukken and James A. Overdahl, Financial Product Fundamentals: A Guide for Lawyers § 18:2 (5th ed.2004).

C. Stock Option Backdating

“Stock option backdating” is a phrase that describes a practice in which the record of the option grant deviates from the actual grant date. A stock option is said to have been “backdated” if it was actually granted on one date, but the option itself is dated and is “recorded” on the books of the company as granted on an earlier date. Backdating a stock option is not necessarily improper. Backdating may be improper, however, if the practice misleads shareholders.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hultman v. Mattson
N.D. California, 2024
Apple, Inc. v. Superior Court
California Court of Appeal, 2017
Apple Inc. v. Superior Court of Santa Clara Cnty.
227 Cal. Rptr. 3d 8 (California Court of Appeals, 5th District, 2017)
Carlucci v. Han
886 F. Supp. 2d 497 (E.D. Virginia, 2012)
Betz v. Trainer Wortham & Co.
829 F. Supp. 2d 860 (N.D. California, 2011)
New York City Employees' Retirement System v. Berry
616 F. Supp. 2d 987 (N.D. California, 2009)
SOMMERS EX REL. FLIR SYSTEMS, INC. v. Lewis
641 F. Supp. 2d 1151 (D. Oregon, 2009)
In Re Brocade Communications Systems, Inc. Derivative Litigation
615 F. Supp. 2d 1018 (N.D. California, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
574 F. Supp. 2d 1046, 2008 U.S. Dist. LEXIS 69527, 2008 WL 4061075, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-maxim-integrated-products-inc-deriv-lit-cand-2008.